Evidence map›Paper›PMID 38113525›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2024

Relationship Between Tobacco Product Use and Health-Related Quality of Life Among Individuals With COPD in Waves 1-5 (2013-2019) of the Population Assessment of Tobacco and Health Study.

Laura M Paulin, Michael J Halenar, Kathryn C Edwards, Kristin Lauten, Kristie Taylor, Mary Brunette, Susanne Tanski, Todd MacKenzie, Cassandra A Stanton, Dorothy Hatsukami and 13 more

Erratum issuedAbstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Laura M PaulinGeisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, New Hampshire, United States.
Michael J HalenarBehavioral Health and Health Policy Practice, Westat, Rockville, Maryland, United States.
Kathryn C EdwardsBehavioral Health and Health Policy Practice, Westat, Rockville, Maryland, United States.
Kristin LautenBehavioral Health and Health Policy Practice, Westat, Rockville, Maryland, United States.
Kristie TaylorBehavioral Health and Health Policy Practice, Westat, Rockville, Maryland, United States.
Mary BrunetteGeisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, New Hampshire, United States.
Susanne TanskiGeisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, New Hampshire, United States.
Todd MacKenzieGeisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, New Hampshire, United States.
Cassandra A StantonBehavioral Health and Health Policy Practice, Westat, Rockville, Maryland, United States.
Dorothy HatsukamiDepartment of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota, United States.
Andrew HylandDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.
Martin C MahoneyDepartment of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.
Ray NiauraSchool of Global Public Health, New York University, New York, New York, United States.
Dennis TrinidadUniversity of California at San Diego, La Jolla, California, United States.
Carlos BlancoNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, United States.
Wilson ComptonNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, United States.
Lisa D GardnerCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, United States.
Heather L KimmelNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, United States.
K Michael CummingsDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, United States.
Dana LautersteinCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, United States.
Ester J RohCenter for Tobacco Products, Food and Drug Administration, Silver Spring, Maryland, United States.
Daniela MarshallNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, United States.
James D SargentGeisel School of Medicine at Dartmouth, The C. Everett Koop Institute at Dartmouth, Hanover, New Hampshire, United States.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
FDA CTP HHSN27101100027CFDA CTP HHSN27120160001CNCI NIH HHS P30 CA023108NIH NIDA HHSN27101100027CNIH NIDA HHSN27120160001C
6 · The paper itself

Abstract

Introduction: We examined the association between tobacco product use and health-related quality of life (HRQoL) among individuals with chronic obstructive pulmonary disease (COPD) in Waves 1-5 of the Population Assessment of Tobacco and Health (PATH) Study. Methods: Adults ≥40 years with an ever COPD diagnosis were included in cross-sectional (Wave 5) and longitudinal (Waves 1 to 5) analyses. Tobacco use included 13 mutually exclusive categories of past 30-day (P30D) single use and polyuse with P30D exclusive cigarette use and ≥5-year cigarette cessation as reference groups. Multivariable linear regression and generalized estimating equations (GEE) were used to examine the association between tobacco use and HRQoL as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 questionnaire. Results: Of 1670 adults, 79.4% ever used cigarettes; mean (standard error [SE]) pack years was 30.9 (1.1). In cross-sectional analysis, P30D exclusive cigarette use, and e-cigarette/cigarette dual use were associated with worse HRQoL compared to ≥5-year cigarette cessation. Compared to P30D exclusive cigarette use, never tobacco use and ≥5-year cigarette cessation were associated with better HRQoL, while e-cigarette/cigarette dual use had worse HRQoL. Longitudinally (n=686), e-cigarette/cigarette dual use was associated with worsening HRQoL compared to both reference groups. Only never tobacco use was associated with higher HRQoL over time compared to P30D exclusive cigarette use. Conclusions: E-cigarette/cigarette dual use was associated with worse HRQoL compared to ≥5-year cigarette cessation and exclusive cigarette use. Never use and ≥5-year cigarette cessation were the only categories associated with higher HRQoL compared to exclusive cigarette use. Findings highlight the importance of complete smoking cessation for individuals with COPD.

Indexed as

cigaretteCOPDe-cigaretteepidemiologyprevention

Identifiers

PMID38113525
PMCPMC10913919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.